title: References - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 417/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  References
  |
  MIMS Online, Palivizumab ;Accessed 24/03/2020.
  Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013:CD006602.
  Australian Medicines Handbook. Palivizumab ; Accessed 24/03/2020.
  The Australian Immunisation Handbook. Respiratory syncytial virus monoclonal antibodies. 10th Edition 2013 (updated January 2014).
  Homaira N, Oei JL, Mallitt KA, Abdel-Latif ME, Hilder L, Bajuk B, Lui K, Ferson M, Nurkic A, Chambers GM, Rawlinson W, Snelling T, Jaffe A. High burden of RSV hospitalization in very young children: a data linkage study. Epidemiol Infect. 2016;144:1612-21.
  Sanders SL, Agwan S, Hassan M, van Driel ML, Del Mar CB. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Cochrane Database Syst Rev. 2019;8:CD009417.
  Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2016;7:CD007743.
  Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr., Connor EM, Sondheimer HM, Cardiac Synagis Study G. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-40.
  Evaluation summary. Palivizumab for prevention of serious lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in infants at high risk of RSV disease. South Australian Medicines Evaluation Panel. 2015.
  American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415-20.
  Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927-36.
  American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620-38.
  |
  Original version Date: 28/05/20
  |
  Author: NeoMed Consensus Group
  |
  Current Version number: 2
  |
  Current Version Date: 16/11/2020
  |
  Risk Rating: Low
  |
  Due for Review: 16/11/2025
  |
  Approved by: DTC
  |
  Approval Date: TBA
  |
  |
  | |